Matthew Cooperberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9259312/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
2	Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 1117-1123.	1.6	917
3	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 1938-1942.	0.4	592
4	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	1.9	553
5	Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA - Journal of the American Medical Association, 2015, 314, 80.	7.4	543
6	Renal cell cancer stage migration. Cancer, 2008, 113, 78-83.	4.1	535
7	The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. Journal of Clinical Oncology, 2004, 22, 2141-2149.	1.6	528
8	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 62, 976-983.	1.9	518
9	Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. Journal of Urology, 2007, 178, S14-9.	0.4	368
10	Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer, 2008, 112, 2664-2670.	4.1	361
11	The CAPRAâ€ S score. Cancer, 2011, 117, 5039-5046.	4.1	359
12	National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 981-989.	6.3	323
13	Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. Journal of Clinical Oncology, 2013, 31, 1428-1434.	1.6	323
14	Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. Journal of Clinical Oncology, 2011, 29, 235-241.	1.6	321
15	THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRY. Journal of Urology, 2004, 171, 1393-1401.	0.4	315
16	The Changing Face of Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 8146-8151.	1.6	293
17	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
18	Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. Journal of the National Cancer Institute, 2009, 101, 878-887.	6.3	287

#	Article	IF	CITATIONS
19	Comparative riskâ€adjusted mortality outcomes after primary surgery, radiotherapy, or androgenâ€deprivation therapy for localized prostate cancer. Cancer, 2010, 116, 5226-5234.	4.1	286
20	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq0 0 0 rgBT / Clinical Oncology, 2016, 34, 2182-2190.	Overlock 10 1.6	0 Tf 50 707 1 285
21	Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From) Tj ETQq1	l 0.784314 0.4	rgBT /Overlo
22	Active Surveillance for Prostate Cancer: Progress and Promise. Journal of Clinical Oncology, 2011, 29, 3669-3676.	1.6	264
23	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1126.	7.4	261
24	Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 228-234.	1.6	259
25	Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1205.	7.4	253
26	Active surveillance for earlyâ€stage prostate cancer. Cancer, 2008, 112, 1650-1659.	4.1	252
27	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.8	247
28	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	7.1	219
29	Genomic Markers in Prostate Cancer Decision Making. European Urology, 2018, 73, 572-582.	1.9	201
30	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	10.7	182
31	Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. European Urology, 2015, 67, 326-333.	1.9	178
32	Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. Journal of Clinical Oncology, 2011, 29, 2795-2800.	1.6	177
33	High-risk prostate cancer in the United States, 1990–2007. World Journal of Urology, 2008, 26, 211-218.	2.2	173
34	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 149.	7.4	172
35	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	1.9	166
36	Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry. European Urology, 2015, 68, 600-608.	1.9	156

#	Article	IF	CITATIONS
37	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
38	Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer. Journal of Urology, 2015, 193, 807-811.	0.4	148
39	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
40	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
41	Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology, 2005, 66, 1060-1065.	1.0	135
42	Use of social media in urology: data from the <scp>A</scp> merican <scp>U</scp> rological <scp>A</scp> ssociation (<scp>AUA</scp>). BJU International, 2014, 113, 993-998.	2.5	135
43	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006, 107, 2384-2391.	4.1	129
44	Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 2013, 64, 905-915.	1.9	128
45	Urethral Reconstruction for Traumatic Posterior Urethral Disruption: Outcomes of a 25-Year Experience. Journal of Urology, 2007, 178, 2006-2010.	0.4	127
46	Time Trends and Characteristics of Men Choosing Watchful Waiting for Initial Treatment of Localized Prostate Cancer: Results From CaPSURE. Journal of Urology, 2003, 170, 1804-1807.	0.4	125
47	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.4	122
48	Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review. European Urology, 2014, 65, 1023-1031.	1.9	118
49	Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy. Journal of Clinical Oncology, 2009, 27, 4306-4313.	1.6	115
50	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2349-2356.	2.5	111
51	Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU International, 2016, 117, 836-842.	2.5	111
52	Impact of ⁶⁸ Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1956-1961.	5.0	111
53	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. European Urology, 2014, 65, 1171-1177.	1.9	110
54	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. European Urology, 2017, 71, 729-737.	1.9	110

#	Article	IF	CITATIONS
55	Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. European Urology, 2020, 78, 296-298.	1.9	110
56	Primary treatments for clinically localised prostate cancer: a comprehensive lifetime costâ€utility analysis. BJU International, 2013, 111, 437-450.	2.5	109
57	Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). European Urology, 2020, 77, 713-724.	1.9	108
58	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	3.7	107
59	The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer. Journal of Urology, 2011, 185, 1656-1660.	0.4	103
60	VALIDATION OF THE KATTAN PREOPERATIVE NOMOGRAM FOR PROSTATE CANCER RECURRENCE USING A COMMUNITY BASED COHORT: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CAPSURE). Journal of Urology, 2004, 171, 2255-2259.	0.4	100
61	Traditional and Virtual Congress Meetings During the COVID-19 Pandemic and the Post-COVID-19 Era: Is it Time to Change the Paradigm?. European Urology, 2020, 78, 301-303.	1.9	100
62	Biomarkers in prostate cancer surveillance and screening: past, present, and future. Therapeutic Advances in Urology, 2013, 5, 318-329.	2.0	99
63	Treatment Trends for Stage I Renal Cell Carcinoma. Journal of Urology, 2011, 186, 394-399.	0.4	95
64	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. European Urology, 2018, 74, 197-203.	1.9	93
65	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	1.9	93
66	Decreasing Size at Diagnosis of Stage 1 Renal Cell Carcinoma: Analysis From the National Cancer Data Base, 1993 to 2004. Journal of Urology, 2008, 179, 2131-2135.	0.4	91
67	Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells. Cancer Research, 2004, 64, 704-710.	0.9	90
68	Expected population impacts of discontinued prostateâ€specific antigen screening. Cancer, 2014, 120, 3519-3526.	4.1	90
69	Stroke in surgery of the thoracic aorta: Incidence, impact, etiology, and prevention. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 935-945.	0.8	88
70	A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU International, 2013, 112, E67-75.	2.5	86
71	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases, 2020, 23, 517-526.	3.9	80
72	Geographic Distribution of Urologists Throughout the United States Using a County Level Approach. Journal of Urology, 2009, 181, 760-766.	0.4	79

#	Article	IF	CITATIONS
73	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017, 15, 60-66.e2.	1.9	79
74	Urologist Density and County-Level Urologic Cancer Mortality. Journal of Clinical Oncology, 2010, 28, 2499-2504.	1.6	78
75	Racial Variation in Prostate Cancer Upgrading and Upstaging Among Men with Low-risk Clinical Characteristics. European Urology, 2015, 67, 451-457.	1.9	78
76	Percutaneous neuromodulation. Urologic Clinics of North America, 2005, 32, 71-78.	1.8	76
77	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology, 2018, 1, 78-82.	5.4	74
78	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	1.9	72
79	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	1.9	72
80	The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. European Urology, 2017, 71, 705-709.	1.9	72
81	Androgen Deprivation Therapy and Cardiovascular Risk. Journal of Clinical Oncology, 2011, 29, 3510-3516.	1.6	70
82	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	3.9	70
83	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 491-495.	0.4	69
84	ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 1126-1131.	0.4	69
85	Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castrationâ€resistant prostate cancer, and mortality after radical prostatectomy. Cancer, 2014, 120, 197-204.	4.1	69
86	How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer:data from CaPSURE. Urology, 2003, 61, 190-196.	1.0	65
87	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncology, 2016, 2, 890.	7.1	65
88	The <scp>M</scp> elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	2.5	64
89	Limitations of Basing Screening Policies on Screening Trials. Medical Care, 2013, 51, 295-300.	2.4	63
90	THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE). Journal of Urology, 2005, 173, 1132-1138.	0.4	62

#	Article	IF	CITATIONS
91	Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. International Journal of Molecular Sciences, 2021, 22, 4367.	4.1	62
92	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	1.9	61
93	Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer, 2011, 117, 283-289.	4.1	59
94	Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Journal of Comparative Effectiveness Research, 2013, 2, 445-460.	1.4	59
95	Transâ€ <scp>P</scp> acific variation in outcomes for men treated with primary androgenâ€deprivation therapy (<scp>ADT</scp>) for prostate cancer. BJU International, 2016, 117, 102-109.	2.5	57
96	How does robotâ€assisted radical prostatectomy (<scp>RARP</scp>) compare with open surgery in men with highâ€risk prostate cancer?. BJU International, 2013, 112, E314-20.	2.5	56
97	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. European Journal of Cancer, 2015, 51, 817-824.	2.8	56
98	Prostate Cancer Registries: Current Status and Future Directions. European Urology, 2016, 69, 998-1012.	1.9	56
99	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology, 2016, 96, 171-176.	1.0	55
100	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	1.9	55
101	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. European Urology, 2018, 74, 444-452.	1.9	55
102	Health Related Quality of Life Significance of Single Pad Urinary Incontinence Following Radical Prostatectomy. Journal of Urology, 2003, 170, 512-515.	0.4	54
103	Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. European Urology, 2010, 57, 622-630.	1.9	54
104	OBESITY AND PROSTATE CANCER CLINICAL RISK FACTORS AT PRESENTATION: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 732-736.	0.4	53
105	Adequacy of lymphadenectomy among men undergoing robotâ€assisted laparoscopic radical prostatectomy. BJU International, 2010, 105, 88-92.	2.5	53
106	The quantitative Gleason score improves prostate cancer risk assessment. Cancer, 2012, 118, 6046-6054.	4.1	53
107	Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer and Prostatic Diseases, 2013, 16, 391-397.	3.9	53
108	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 2015, 107, djv261.	6.3	53

#	Article	IF	CITATIONS
109	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology, 2018, 73, 168-175.	1.9	53
110	Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	1.9	53
111	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 5471-5478.	7.0	52
112	Trends in Regionalization of Inpatient Care for Urological Malignancies, 1988 to 2002. Journal of Urology, 2007, 178, 2103-2108.	0.4	51
113	Gender differences in subcutaneous and perirenal fat distribution. Surgical and Radiologic Anatomy, 2010, 32, 879-882.	1.2	51
114	Intermediate-risk Prostate Cancer: Stratification and Management. European Urology Oncology, 2020, 3, 270-280.	5.4	51
115	Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology, 2005, 65, 882-887.	1.0	50
116	Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer. Cancer, 2006, 106, 789-795.	4.1	50
117	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. Journal of Urology, 2016, 195, 321-329.	0.4	50
118	Health Related Quality of Life in Patients Treated With Multimodal Therapy for Prostate Cancer. Journal of Urology, 2008, 180, 2415-2422.	0.4	49
119	Patients With Primary Hyperparathyroidism—Why Do Some Form Stones?. Journal of Urology, 2009, 181, 2141-2145.	0.4	49
120	Preoperative Frailty Is Associated With Discharge to Skilled or Assisted Living Facilities After Urologic Procedures of Varying Complexity. Urology, 2016, 97, 25-32.	1.0	49
121	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. Journal of Urology, 2018, 199, 1202-1209.	0.4	49
122	Realâ€world outcomes of sipuleucelâ€T treatment in PROCEED, a prospective registry of men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 4172-4180.	4.1	49
123	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
124	The epidemiology of high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 331-336.	1.8	48
125	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the <scp>S</scp> hared <scp>E</scp> qual <scp>A</scp> ccess <scp>R</scp> egional <scp>C</scp> ancer <scp>H</scp> ospital (<scp>SEARCH</scp>) database. BJU International, 2014, 114, 661-666.	2.5	46
126	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. Journal of Molecular Diagnostics, 2016, 18, 395-406.	2.8	46

#	Article	IF	CITATIONS
127	Thresholds for <scp>PSA</scp> doubling time in men with nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E80-E86.	2.5	46
128	Active Surveillance in Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1898-1904.	1.6	46
129	Genomic biomarkers in prostate cancer. Translational Andrology and Urology, 2018, 7, 459-471.	1.4	46
130	Impact of the United States Preventive Services Task Force †D' recommendation on prostate cancer screening and staging. Current Opinion in Urology, 2017, 27, 205-209.	1.8	45
131	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. European Urology, 2018, 73, 215-223.	1.9	45
132	Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. European Urology, 2019, 75, 950-958.	1.9	45
133	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers, 2021, 13, 2047.	3.7	45
134	Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncology, 2022, 8, 50.	7.1	45
135	Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. European Urology, 2020, 78, 304-306.	1.9	44
136	Who is the average patient presenting with prostate cancer?. Urology, 2005, 66, 76-82.	1.0	43
137	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU International, 2014, 114, E18-E24.	2.5	43
138	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.4	43
139	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology, 2016, 89, 69-75.	1.0	43
140	Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU International, 2010, 106, 1022-1029.	2.5	42
141	Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. European Urology, 2015, 68, 480-486.	1.9	42
142	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. PLoS ONE, 2014, 9, e98597.	2.5	41
143	Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer and Prostatic Diseases, 2015, 18, 149-154.	3.9	41
144	Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer and Prostatic Diseases, 2017, 20, 72-78.	3.9	41

#	Article	IF	CITATIONS
145	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. JAMA Network Open, 2020, 3, e2031349.	5.9	41
146	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Journal of Clinical Oncology, 2022, 40, 3110-3114.	1.6	41
147	Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?. Prostate Cancer and Prostatic Diseases, 2016, 19, 380-384.	3.9	40
148	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology, 2017, 71, 750-759.	1.9	40
149	Minimal Impact of Clinical Stage on Prostate Cancer Prognosis Among Contemporary Patients With Clinically Localized Disease. Journal of Urology, 2010, 184, 114-119.	0.4	39
150	Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE. Journal of Urology, 2003, 170, 905-908.	0.4	38
151	Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery, 2004, 135, 452-453.	1.9	38
152	Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 155-160.	1.6	38
153	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer, 2014, 120, 1263-1271.	4.1	38
154	Diagnostic associations of gene expression signatures in prostate cancer tissue. Current Opinion in Urology, 2015, 25, 65-70.	1.8	38
155	The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU International, 2010, 105, 472-475.	2.5	37
156	Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2012, 15, 100-105.	3.9	37
157	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World Journal of Urology, 2019, 37, 1255-1261.	2.2	37
158	Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSUREâ,,¢ Registry. Journal of Urology, 2014, 191, 964-970.	0.4	36
159	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer, 2017, 123, 4574-4582.	4.1	36
160	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 136-143.	3.9	36
161	Clinical Utility of 4Kscore [®] , ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. Journal of Urology, 2021, 205, 452-460.	0.4	36
162	Genomic Prostate Score, PI-RADSâ,,¢ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. Journal of Urology, 2019, 201, 300-307.	0.4	36

#	Article	IF	CITATIONS
163	Candidate quality of care indicators for localized bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 435-442.	1.6	35
164	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	5.0	35
165	A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. Journal of Urology, 2019, 202, 702-709.	0.4	35
166	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. European Urology, 2018, 74, 668-675.	1.9	34
167	Adequacy of a Single 24-Hour Urine Collection for Metabolic Evaluation of Recurrent Nephrolithiasis. Journal of Urology, 2010, 184, 579-583.	0.4	33
168	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine, 2018, 168, 1.	3.9	33
169	Cystic pelvic pathology presenting as falsely elevated postvoid residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. Urology, 2000, 55, 590.	1.0	32
170	Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection. Fertility and Sterility, 2005, 84, 672-677.	1.0	32
171	Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Medical Informatics and Decision Making, 2010, 10, 34.	3.0	32
172	The example of CaPSURE: lessons learned from a national disease registry. World Journal of Urology, 2011, 29, 265-271.	2.2	32
173	Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer and Prostatic Diseases, 2012, 15, 374-379.	3.9	32
174	Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. European Urology, 2013, 63, 936-940.	1.9	32
175	Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. Cancer, 2014, 120, 507-512.	4.1	32
176	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. European Urology Oncology, 2018, 1, 386-394.	5.4	32
177	Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World Journal of Urology, 2019, 37, 2147-2153.	2.2	32
178	Obesity, race, and longâ€ŧerm prostate cancer outcomes. Cancer, 2020, 126, 3733-3741.	4.1	32
179	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	1.9	32
180	Defining high quality health care. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 411-416.	1.6	30

#	Article	IF	CITATIONS
181	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	4.1	30
182	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. European Urology, 2018, 74, 26-33.	1.9	30
183	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	1.8	30
184	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	1.9	30
185	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	7.1	30
186	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.4	30
187	Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Urology Reports, 2004, 5, 166-172.	2.2	29
188	In Vivo Tumor Grading of Prostate Cancer Using Quantitative ¹¹¹ In-Capromab Pendetide SPECT/CT. Journal of Nuclear Medicine, 2010, 51, 31-36.	5.0	29
189	Impact of androgen deprivation on physical wellâ€being in patients with prostate cancer. Cancer, 2011, 117, 4406-4413.	4.1	29
190	Outcomes for Radical Prostatectomy: Is It the Singer, the Song, or Both?. Journal of Clinical Oncology, 2012, 30, 476-478.	1.6	28
191	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	1.9	28
192	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. European Urology, 2020, 78, 335-344.	1.9	28
193	Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 333-337.	3.9	27
194	Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era. Urology, 2013, 82, 60-66.	1.0	26
195	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunology Research, 2016, 4, 948-958.	3.4	26
196	A Simple Schema for Informed Decision Making About Prostate Cancer Screening. Annals of Internal Medicine, 2014, 161, 441.	3.9	25
197	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e299-e309.	1.9	25
198	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. Journal of Urology, 2020, 203, 331-337.	0.4	25

#	Article	IF	CITATIONS
199	Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology, 2022, 8, 41.	7.1	25
200	The impact of pathologic staging on the longâ€ŧerm oncologic outcomes of patients with clinically highâ€ŧisk prostate cancer. Cancer, 2014, 120, 1656-1662.	4.1	24
201	Epidemiology of prostate cancer. World Journal of Urology, 2017, 35, 849-849.	2.2	24
202	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 252-260.	3.9	24
203	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29†MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 2022, 112, 106618.	1.8	24
204	Serum Prostate-Specific Antigen for the Early Detection of Prostate Cancer: Always, Never, or Only Sometimes?. Journal of Clinical Oncology, 2011, 29, 345-347.	1.6	23
205	PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer and Prostatic Diseases, 2012, 15, 189-194.	3.9	22
206	Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Current Opinion in Urology, 2014, 24, 288-292.	1.8	22
207	Long-Term Active Surveillance for Prostate Cancer: Answers and Questions. Journal of Clinical Oncology, 2015, 33, 238-240.	1.6	22
208	Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer and Prostatic Diseases, 2016, 19, 423-428.	3.9	22
209	Factors predicting skeletalâ€related events in patients with bone metastatic castrationâ€resistant prostate cancer. Cancer, 2017, 123, 1528-1535.	4.1	22
210	Number of Unfavorable Intermediateâ€Risk Factors Predicts Pathologic Upstaging and Prostate Cancerâ€6pecific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate, 2017, 77, 154-163.	2.3	22
211	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	3.9	22
212	Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. Journal of Urology, 2019, 202, 506-510.	0.4	22
213	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS ONE, 2017, 12, e0185535.	2.5	22
214	Prostate cancer 2004: insights from national disease registries. Oncology, 2004, 18, 1239-47; discussion 1248-50, 1256-8.	0.5	22
215	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	1.5	21
216	Variation in prostate cancer treatment associated with population density of the county of residence. Prostate Cancer and Prostatic Diseases, 2016, 19, 174-179.	3.9	21

#	Article	IF	CITATIONS
217	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology, 2019, 2, 685-690.	5.4	21
218	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. Journal of Urology, 2021, 205, 761-768.	0.4	21
219	Improper Retrograde Urethrogram Technique Leads to Incorrect Diagnosis. Journal of Urology, 2009, 182, 716-717.	0.4	20
220	Disproportionate Presentation of High Risk Prostate Cancer in a Safety Net Health System. Journal of Urology, 2010, 184, 1931-1936.	0.4	20
221	Re-Examining Racial Disparities in Prostate Cancer Outcomes. Journal of Clinical Oncology, 2013, 31, 2979-2980.	1.6	20
222	Positive surgical margins in radical prostatectomy patients do not predict longâ€ŧerm oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) cohort. BJU International, 2016, 117, 244-248.	2.5	20
223	Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 40-41.	1.6	20
224	The AUA Quality Registry: Engaging Stakeholders to Improve the Quality ofÂCare for Patients with Prostate Cancer. Urology Practice, 2017, 4, 30-35.	0.5	20
225	Poorly controlled diabetes increases the risk of metastases and castrationâ€resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer, 2019, 125, 2861-2867.	4.1	20
226	Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1917-1925.	2.5	20
227	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research, 2014, 20, 5302-5310.	7.0	19
228	Implications of the New AUA Guidelines on Prostate Cancer Detection in the U.S Current Urology Reports, 2014, 15, 420.	2.2	19
229	Active Surveillance for Low-Risk Prostate Cancer—An Evolving International Standard of Care. JAMA Oncology, 2017, 3, 1398.	7.1	19
230	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. European Urology, 2017, 72, 307-314.	1.9	19
231	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. Journal of Urology, 2017, 197, 369-375.	0.4	19
232	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.4	19
233	Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood, 1998, 92, 672-82.	1.4	19
234	Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer and Prostatic Diseases, 2014, 17, 246-251.	3.9	18

#	Article	IF	CITATIONS
235	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology, 2017, 103, 173-178.	1.0	18
236	High-throughput, Efficient, and Unbiased Capture of Small RNAs from Low-input Samples for Sequencing. Scientific Reports, 2019, 9, 2262.	3.3	18
237	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology, 2017, 108, 129-134.	1.0	17
238	Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. JCO Clinical Cancer Informatics, 2019, 3, 1-8.	2.1	17
239	Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. European Urology, 2022, 81, 219-221.	1.9	17
240	Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: Case report and review of the literature. Annals of Diagnostic Pathology, 2001, 5, 162-167.	1.3	16
241	Prostate cancer risk assessment. Cancer, 2008, 113, 3062-3066.	4.1	16
242	Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. Journal of Urology, 2017, 198, 671-677.	0.4	16
243	Predictors of operative time during radical retropubic prostatectomy and robotâ€assisted laparoscopic prostatectomy. International Journal of Urology, 2017, 24, 618-623.	1.0	16
244	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 289.e11-289.e17.	1.6	16
245	Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. European Urology, 2020, 77, 563-572.	1.9	16
246	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2019, 202, 696-701.	0.4	16
247	Management of localized prostate cancer in men over 65 years. Current Opinion in Urology, 2009, 19, 309-314.	1.8	15
248	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. European Urology, 2015, 67, 1019-1025.	1.9	15
249	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 547-554.	2.5	15
250	Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. Journal of Urology, 2017, 198, 1309-1315.	0.4	15
251	Validation of the 2015 prostate cancer grade groups for predicting longâ€ŧerm oncologic outcomes in a shared equalâ€access health system. Cancer, 2017, 123, 4122-4129.	4.1	15
252	Obese patients with castrationâ€resistant prostate cancer may be at a lower risk of allâ€cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	2.5	15

#	Article	IF	CITATIONS
253	Predictors of skeletalâ€related events and mortality in men with metastatic, castrationâ€resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer, 2019, 125, 4003-4010.	4.1	15
254	Obesity, risk of biochemical recurrence, and prostateâ€specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU International, 2019, 124, 69-75.	2.5	15
255	Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. Journal of Urology, 2002, 168, 491-5.	0.4	15
256	Risk-Based Prostate Cancer Screening: Who and How?. Current Urology Reports, 2013, 14, 192-198.	2.2	14
257	Updated Survey of Social Media Use by Members of the American Urological Association. Urology Practice, 2015, 2, 138-143.	0.5	14
258	Role of Active Surveillance in the Management of Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 202-206.	2.1	13
259	Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?. BJU International, 2015, 116, 713-720.	2.5	13
260	Clinical Utility of Biomarkers in Localized Prostate Cancer. Current Oncology Reports, 2016, 18, 30.	4.0	13
261	Impact of prior local therapy on overall survival in men with metastatic castrationâ€resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. International Journal of Urology, 2018, 25, 998-1004.	1.0	13
262	Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 633-635.	3.9	13
263	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. European Urology Focus, 2019, 5, 155-158.	3.1	13
264	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectrum, 2021, 5, pkab023.	2.9	13
265	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.	1.9	13
266	Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer and Prostatic Diseases, 2014, 17, 91-96.	3.9	12
267	A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2014, 17, 174-179.	3.9	12
268	ls clinical stage T2c prostate cancer an intermediate―or highâ€risk disease?. Cancer, 2015, 121, 1414-1421.	4.1	12
269	Prostateâ€specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 362-366.	1.0	12
270	Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	2.5	12

#	Article	IF	CITATIONS
271	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	1.6	12
272	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. Practical Radiation Oncology, 2018, 8, 307-316.	2.1	12
273	Active surveillance for intermediate-risk prostate cancer. Current Opinion in Urology, 2019, 29, 605-611.	1.8	12
274	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. European Urology, 2020, 78, 515-517.	1.9	12
275	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. European Urology, 2020, 78, 248-255.	1.9	12
276	Association Between Twitter Reception at a National Urology Conference and Future Publication Status. European Urology Focus, 2021, 7, 214-220.	3.1	12
277	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse Journal of Clinical Oncology, 2014, 32, 5003-5003.	1.6	12
278	Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World Journal of Urology, 2014, 32, 1061-1066.	2.2	11
279	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. Journal of Urology, 2015, 193, 1232-1238.	0.4	11
280	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 2016, 96, 116-120.	1.0	11
281	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. European Urology Focus, 2017, 3, 480-486.	3.1	11
282	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. Journal of Urology, 2018, 200, 541-548.	0.4	11
283	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 116-126.	0.8	11
284	Interpretation of Domain Scores on the EPIC—How Does the Domain Score Translate into Functional Outcomes?. Journal of Urology, 2019, 202, 1150-1158.	0.4	11
285	A new look at prostate cancer treatment complications. Nature Reviews Clinical Oncology, 2014, 11, 304-305.	27.6	10
286	Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 658-662.	1.0	10
287	Declining Incidence Rates of Prostate Cancer in the United States. JAMA Oncology, 2017, 3, 1623.	7.1	10
288	Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 663.e9-663.e14.	1.6	10

#	Article	IF	CITATIONS
289	Prostate Cancer Markers. Cancer Treatment and Research, 2018, 175, 55-86.	0.5	10
290	The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2463-2474.	2.5	10
291	Natural language processing systems for pathology parsing in limited data environments with uncertainty estimation. JAMIA Open, 2020, 3, 431-438.	2.0	10
292	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
293	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large―cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	5.5	10
294	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science, 2022, 37, 113-119.	0.4	10
295	Urinary Citrate Levels Do Not Correlate with Urinary pH in Patients with Urinary Stone Formation. Urology, 2007, 70, 634-637.	1.0	9
296	Factors associated with downgrading in patients with high grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 442-447.	1.6	9
297	Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) database. BJU International, 2018, 122, 592-598.	2.5	9
298	Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer and Prostatic Diseases, 2019, 22, 117-124.	3.9	9
299	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592.	4.1	9
300	Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2020, 204, 511-517.	0.4	9
301	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1216-1221.	0.4	9
302	Prostate cancer screening in low- and middle- income countries: the Mexican case. Salud Publica De Mexico, 2019, 61, 542.	0.4	9
303	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. Journal of Urology, 2022, 207, 1029-1037.	0.4	9
304	NATIONAL TRENDS IN TREATMENT OF STAGE I RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 319-319.	0.4	8
305	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur	1.9	8
306	Progress in Management of Low-risk Prostate Cancer: How Registries May Change the World. European Urology, 2015, 67, 51-52.	1.9	8

#	Article	IF	CITATIONS
307	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. Journal of Clinical Oncology, 2016, 34, 3586-3587.	1.6	8
308	Validation of a bone scan positivity risk table in nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2016, 118, 570-577.	2.5	8
309	Race does not predict the development of metastases in men with nonmetastatic castrationâ€resistant prostate cancer. Cancer, 2016, 122, 3848-3855.	4.1	8
310	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 329-332.	1.9	8
311	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate, 2017, 77, 1592-1600.	2.3	8
312	Estimating and comparing cancer progression risks under varying surveillance protocols. Annals of Applied Statistics, 2018, 12, 1773-1795.	1.1	8
313	The Gender Pay Gap in Urology. Urology Practice, 2021, 8, 149-154.	0.5	8
314	Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. JAMA Network Open, 2021, 4, e2112214.	5.9	8
315	Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database. Prostate Cancer and Prostatic Diseases, 2022, 25, 690-693.	3.9	8
316	Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. Journal of Urology, 2019, 202, 732-741.	0.4	8
317	Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investigative and Clinical Urology, 2022, 63, 27.	2.0	8
318	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. Journal of Urology, 2022, 207, 832-840.	0.4	8
319	The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2003, 55, 219-38.	3.9	8
320	Are Age-Based Criteria the Best Way to Determine Eligibility for Prostate Cancer Screening?. Annals of Internal Medicine, 2009, 150, 220.	3.9	7
321	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	2.5	7
322	Asia prostate cancer study (A-CaP Study) launch symposium. Prostate International, 2016, 4, 88-96.	2.3	7
323	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate International, 2017, 5, 95-103.	2.3	7
324	PNFBA-07 THE CURRENT MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: DATA FROM THE AQUA REGISTRY. Journal of Urology, 2017, 197, .	0.4	7

#	Article	IF	CITATIONS
325	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. Journal of Urology, 2018, 199, 713-718.	0.4	7
326	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. Journal of Clinical Oncology, 2018, 36, 937-941.	1.6	7
327	Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology, 2019, 131, 157-165.	1.0	7
328	Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clinical Genitourinary Cancer, 2019, 17, e140-e149.	1.9	7
329	Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Medicine, 2020, 9, 125-132.	2.8	7
330	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. Journal of Urology, 2022, 207, 127-136.	0.4	7
331	Impact of the COVID-19 Pandemic on Urological Care Delivery in the United States. Journal of Urology, 2021, 206, 1469-1479.	0.4	7
332	Proximal Bulbar Periurethral Abscess. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 137-138.	1.5	7
333	Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. International Journal of Urology, 2007, 14, 1113-1115.	1.0	6
334	ls computed tomography a necessary part of a metastatic evaluation for castrationâ€resistant prostate cancer? Results from <scp>the Shared Equal Access Regional Cancer Hospital Database</scp> . Cancer, 2016, 122, 222-229.	4.1	6
335	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. International Journal of Urology, 2020, 27, 851-857.	1.0	6
336	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 930.e23-930.e32.	1.6	6
337	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. European Urology Focus, 2021, 7, 1268-1273.	3.1	6
338	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology, 2021, 149, 168-173.	1.0	6
339	Fiveâ€year outcomes from a prospective comparative effectiveness study evaluating externalâ€beam radiotherapy with or without lowâ€doseâ€rate brachytherapy boost for localized prostate cancer. Cancer, 2021, 127, 1912-1925.	4.1	6
340	Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology, 2021, , .	5.4	6
341	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis Journal of Clinical Oncology, 2019, 37, 5035-5035.	1.6	6
342	Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. Journal of Urology, 2022, 207, 592-600.	0.4	6

#	Article	IF	CITATIONS
343	Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. Journal of Urology, 2020, 204, 1236-1241.	0.4	6
344	Will Biomarkers Save Prostate Cancer Screening?. European Urology, 2012, 62, 962-963.	1.9	5
345	Proton Therapy Websites: Information Anarchy Creates Confusion. BJU International, 2015, 115, 183-185.	2.5	5
346	Agent Orange and long-term outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e1-329.e6.	1.6	5
347	Whom to Treat. Urologic Clinics of North America, 2017, 44, 547-555.	1.8	5
348	Clinical risk stratification for prostate cancer: Where are we, and where do we need to go?. Canadian Urological Association Journal, 2017, 11, 101.	0.6	5
349	Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. European Urology, 2019, 76, 743-751.	1.9	5
350	Safety of concomitant therapy with radiumâ€⊋23 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	2.3	5
351	Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry, European Urology Open Science, 2022, 37, 106-112.	0.4	5
352	Prostate-cancer screening. New England Journal of Medicine, 2009, 361, 203; author reply 204-5.	27.0	5
353	Predictors of Regret among Older Men after Stress Urinary Incontinence Treatment Decisions. Journal of Urology, 2022, 207, 885-892.	0.4	5
354	Proton Beam Therapy and Treatment for Localized Prostate Cancer: If You Build It, They Will Come. Archives of Internal Medicine, 2012, 172, 280.	3.8	4
355	Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?. BJU International, 2012, 109, 1520-1524.	2.5	4
356	Implementation of PSA-based active surveillance in prostate cancer. Biomarkers in Medicine, 2014, 8, 747-753.	1.4	4
357	Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer, 2014, 120, 824-832.	4.1	4
358	National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United States. Urology Practice, 2014, 1, 198-204.	0.5	4
359	Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate International, 2014, 2, 50-69.	2.3	4
360	Current Use of Imaging after Primary Treatment of Prostate Cancer. Journal of Urology, 2015, 194, 98-104.	0.4	4

#	Article	IF	CITATIONS
361	Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 425-434.	2.3	4
362	Magnetic Resonance Imaging–targeted Prostate Biopsies: Is the Right Technique the Right Question?. European Urology, 2017, 71, 532-533.	1.9	4
363	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2018, 199, 719-725.	0.4	4
364	Report of the third Asian Prostate CancerÂstudy meeting. Prostate International, 2019, 7, 60-67.	2.3	4
365	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clinical Genitourinary Cancer, 2020, 18, e21-e27.	1.9	4
366	Significant Management Variability of Urethral stricture Disease in United States: Data from the AUA Quality (AQUA) Registry. Urology, 2020, 146, 265-270.	1.0	4
367	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. European Urology, 2021, 79, 141-149.	1.9	4
368	Understanding the Health Characteristics and Treatment Choices of Older Men with Stress Urinary Incontinence. Urology, 2021, 154, 281-287.	1.0	4
369	1362: Nephrolithiasis and the Risk of Cardiovascular Disease. Journal of Urology, 2007, 177, 449-449.	0.4	4
370	Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer Journal of Clinical Oncology, 2016, 34, 119-119.	1.6	4
371	High-risk prostate cancer: treat the prostate. Lancet, The, 2011, 378, 2056-2057.	13.7	3
372	Thwarting High-risk Prostate Cancer: The Right Treatments for the Right Patients. European Urology, 2012, 61, 1107-1109.	1.9	3
373	Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncology, 2016, 12, 2393-2396.	2.4	3
374	Characterization of a "lowâ€risk―cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2017, 24, 611-617.	1.0	3
375	MP93-08 INTERPRETING PATIENT-REPORTED URINARY AND SEXUAL FUNCTION OUTCOMES ACROSS MULTIPLE VALIDATED INSTRUMENTS. Journal of Urology, 2017, 197, .	0.4	3
376	Measuring quality of urology care using a qualified clinical data registry. Current Opinion in Urology, 2018, 28, 329-335.	1.8	3
377	First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes and Control, 2019, 30, 259-269.	1.8	3
378	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	4.1	3

#	Article	IF	CITATIONS
379	Practice patterns and outcomes of equivocalÂbone scans for patients with castration-resistant prostate cancer: ResultsÂfrom SEARCH. Asian Journal of Urology, 2019, 6, 242-248.	1.2	3
380	Does race predict the development of metastases in men who receive androgenâ€deprivation therapy for a biochemical recurrence after radical prostatectomy?. Cancer, 2019, 125, 434-441.	4.1	3
381	Prospective validation of microseminoproteinâ€î² added to the 4Kscore in predicting highâ€grade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	2.5	3
382	Race does not predict skeletalâ€related events and allâ€cause mortality in men with castrationâ€resistant prostate cancer. Cancer, 2020, 126, 3274-3280.	4.1	3
383	Reply to Roderick C.N. van den Bergh, Olivier RouviA re, and Theodorus van der Kwasta€™s Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304–6. Prebiopsy MRI: Through the Looking Glass. European Urology, 2020,	1.9	3
384	Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. Urology, 2021, 149, 181-186.	1.0	3
385	Characteristics of Participants in the American Urological Association Quality (AQUA) Registry and Early Impact of Participation on Quality of Care. Urology Practice, 2021, 8, 209-216.	0.5	3
386	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. Journal of Urology, 2020, 203, 120-127.	0.4	3
387	A pharmacodynamic study of pre-prostatectomy buparlisib in men with high-risk, localized prostate cancer Journal of Clinical Oncology, 2016, 34, e14110-e14110.	1.6	3
388	Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer Journal of Clinical Oncology, 2018, 36, 69-69.	1.6	3
389	Active Surveillance: Very Much "Preferred―for Low-Risk Prostate Cancer. Journal of Urology, 2022, 207, 262-264.	0.4	3
390	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. Journal of Urology, 2022, 207, 1001-1009.	0.4	3
391	Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate, 2022, 82, 366-372.	2.3	3
392	THE UCSF CANCER OF THE PROSTATE RISK ASSESSMENT (CAPRA) SCORE ACCURATELY PREDICTS METASTASIS, PROSTATE CANCER MORTALITY, AND ALL-CAUSE MORTALITY REGARDLESS OF TREATMENT TYPE. Journal of Urology, 2008, 179, 114-115.	0.4	2
393	POSTERIOR TIBIAL NERVE STIMULATION FOR PELVIC FLOOR DYSFUNCTION. , 2008, , 277-283.		2
394	High-risk nonmuscle invasive bladder cancer. Current Opinion in Urology, 2012, 22, 385-389.	1.8	2
395	Early Detection of Prostate Cancer: More Information, More Clarity. European Urology, 2012, 62, 753-755.	1.9	2
396	Adverse Effects of Androgen Deprivation and the Limits of National Tumor Registries. European Urology, 2012, 61, 701-703.	1.9	2

#	Article	IF	CITATIONS
397	Expanding Utilization of Intensity-Modulated Radiotherapy for Prostate Cancer: Soaring Costs, Dubious Benefits. JAMA Internal Medicine, 2013, 173, 1143.	5.1	2
398	Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer. Korean Journal of Urology, 2013, 54, 417.	1.2	2
399	Treatment Trends for Prostate Cancer—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1977.	7.4	2
400	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	1.0	2
401	Identification and Validation of Intrinsic Subtypes of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, S3-S4.	0.8	2
402	MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT?. Journal of Urology, 2017, 197, .	0.4	2
403	The New US Preventive Services Task Force "C―Draft Recommendation for Prostate Cancer Screening. European Urology, 2017, 72, 326-328.	1.9	2
404	PD24-12 OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL-T: PRELIMINARY DATA FROM THE PROCEED REGISTRY. Journal of Urology, 2017, 197, .	0.4	2
405	Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. European Urology, 2017, 71, 492-493.	1.9	2
406	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2
407	Active Surveillance for Prostate Cancer: A 2020 Vision. European Urology, 2020, 77, 687-688.	1.9	2
408	Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends. European Urology, 2021, 79, 42-43.	1.9	2
409	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. Prostate Cancer and Prostatic Diseases, 2022, 25, 238-247.	3.9	2
410	Luminal and basal subtyping of prostate cancer Journal of Clinical Oncology, 2017, 35, 3-3.	1.6	2
411	The diverse genomic landscape of low-risk prostate cancer Journal of Clinical Oncology, 2017, 35, 72-72.	1.6	2
412	Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy Journal of Clinical Oncology, 2018, 36, 118-118.	1.6	2
413	Evolving Indications for Active Surveillance in Low-Risk Localized Prostate Cancer. European Urology Supplements, 2003, 2, 7-13.	0.1	1
414	Specialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USA. Evidence-Based Medicine, 2010, 15, 95-96.	0.6	1

#	Article	IF	CITATIONS
415	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 3532-3533.	4.1	1
416	Editorial Comment. Urology, 2012, 80, 305-306.	1.0	1
417	To Predict the Future, Consider the Present as Well as the Past. European Urology, 2012, 62, 53-54.	1.9	1
418	Editorial Comment. Urology, 2015, 85, 1223.	1.0	1
419	MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	1
420	When to Start Prostate Cancer Screening and When to Stop: Insights from Göteborg. Journal of Urology, 2016, 195, 1325-1326.	0.4	1
421	Why the prostate arm of the PLCO trial failed and what it has taught us. Nature Reviews Urology, 2016, 13, 439-440.	3.8	1
422	Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013–4. European Urology, 2016, 69, 1015.	1.9	1
423	PD40-07 DOES EARLY PSADT (EPSADT) AFTER RADICAL PROSTATECTOMY, CALCULATED PRIOR TO PSA RECURRENCE, CORRELATE WITH PROSTATE CANCER (PC) OUTCOMES? RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2017, 197, .	0.4	1
424	PD10-09 EFFECT OF DEHYDRATED HUMAN AMNION/CHORION MEMBRANE ALLOGRAFT ON URINARY CONTINENCE FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	1
425	PD18-08 PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST-QA/RP2 CONSORTIUM. Journal of Urology, 2017, 197, .	0.4	1
426	What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management. European Urology, 2017, 71, 389-390.	1.9	1
427	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clinical Genitourinary Cancer, 2017, 15, 93-99.	1.9	1
428	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy ofÂthe Mid 1990s for Localized Prostate Cancer. Urology Practice, 2018, 5, 471-479.	0.5	1
429	Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. Clinical Genitourinary Cancer, 2019, 17, e930-e938.	1.9	1
430	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCHÂdatabase. Cancer Causes and Control, 2021, 32, 189-197.	1.8	1
431	Reply by Authors. Journal of Urology, 2021, 205, 339-340.	0.4	1
432	The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy. Urology Practice, 2021, 8, 238-245.	0.5	1

#	Article	IF	CITATIONS
433	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	1.0	1
434	1105: Stage Migration in Renal Cell Carcinoma Patients Demonstrated by Analysis of the National Cancer Database, 1993-2003. Journal of Urology, 2006, 175, 355-355.	0.4	1
435	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging:. Journal of Urology, 2002, , 491-495.	0.4	1
436	Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use Journal of Clinical Oncology, 2016, 34, 193-193.	1.6	1
437	Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry Journal of Clinical Oncology, 2016, 34, 194-194.	1.6	1
438	Incidence of intrathoracic (IT) metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer (PC) Journal of Clinical Oncology, 2017, 35, 5056-5056.	1.6	1
439	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry Journal of Clinical Oncology, 2018, 36, e17018-e17018.	1.6	1
440	Complex biologic heterogeneity of de novo hormone naÃ ⁻ ve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment Journal of Clinical Oncology, 2019, 37, 5055-5055.	1.6	1
441	Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry Journal of Clinical Oncology, 2016, 34, 5025-5025.	1.6	1
442	Racial disparities in radium-223 treatment in a large real-world population Journal of Clinical Oncology, 2019, 37, 268-268.	1.6	1
443	A multibiomarker approach to predict prostate cancer pathology outcomes Journal of Clinical Oncology, 2019, 37, 58-58.	1.6	1
444	Natural history of an immediately detectable PSA following radical prostatectomy: A description of a contemporary cohort Journal of Clinical Oncology, 2020, 38, 356-356.	1.6	1
445	Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	1
446	Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer, 1997, 4, 210-212.	2.9	0
447	Methods for Chemoprotection and Chemosensitization MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells. , 2000, 35, 609-616.		0
448	Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Prostate Reports, 2004, 2, 5-11.	0.1	0
449	PROSTATE TUMOR VOLUME DOES NOT INDEPENDENTLY PREDICT OUTCOME FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2008, 179, 194-194.	0.4	0
450	Reply to Piet Ost, Alberto Bossi and Gert De Meerleer's Letter to the Editor re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. Eur Urol 2010;57:622–30. European Urology, 2010, 58, e34-e35.	1.9	0

#	Article	IF	CITATIONS
451	Editorial Comment. Urology, 2011, 77, 1336-1337.	1.0	0
452	Re: Radical Prostatectomy Versus Watchful Waiting in Early Prostate Cancer. European Urology, 2011, 60, 868-869.	1.9	0
453	Reply to M. Froehner. Journal of Clinical Oncology, 2011, 29, e282-e282.	1.6	0
454	New types of radiotherapy improve cancer outcome but at what cost?. Nature Reviews Urology, 2012, 9, 415-417.	3.8	0
455	FACTORS ASSOCIATED WITH TREATMENT RECEIVED BY MEN DIAGNOSED WITH PROSTATE CANCER IN QUEENSLAND, AUSTRALIA. BJU International, 2012, 110, E720.	2.5	0
456	Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/i.eururo.2012.04.019. European Urology, 2012, 62, e88.	1.9	0
457	For localized prostate cancer, does technology equal progress?. Nature Reviews Clinical Oncology, 2012, 9, 371-372.	27.6	0
458	Re: Quality-of-life Effects of Prostate-specific Antigen Screening. European Urology, 2013, 63, 1130.	1.9	0
459	Reply to A. Azad et al. Journal of Clinical Oncology, 2013, 31, 3296-3297.	1.6	0
460	Editorial Comment. Journal of Urology, 2014, 192, 80-81.	0.4	0
461	Early Detection of Prostate Cancer. Urologic Clinics of North America, 2014, 41, xiii.	1.8	0
462	Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer—Results from the SEARCH database. Cancer Epidemiology, 2015, 39, 1066-1070.	1.9	0
463	Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy, 2015, 14, 753-755.	0.5	0
464	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 2015, 67, 188-190.	1.9	0
465	Rebuttal to Drs. Markovina and Michalski. Brachytherapy, 2015, 14, 761-762.	0.5	0
466	Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa. Annals of Oncology, 2016, 27, vi253.	1.2	0
467	MP31-08 PREOPERATIVE FRAILTY IS ASSOCIATED WITH DISCHARGE TO SKILLED OR ASSISTED LIVING FACILITIES AFTER UROLOGY PROCEDURES OF VARYING COMPLEXITY. Journal of Urology, 2016, 195, .	0.4	0
468	PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	CITATIONS
469	MP79-15 RADICAL PROSTATECTOMY AND THE EFFECT OF CLOSE SURGICAL MARGINS: ANALYSIS FROM THE SEARCH DATABASE. Journal of Urology, 2016, 195, .	0.4	0
470	PD28-05 FACTORS PREDICTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
471	MP09-18 BIOPSY-DETECTED GLEASON PATTERN 5 IS A PARTICULARLY STRONG PREOPERATIVE PREDICTOR OF RECURRENCE, METASTASIS, AND MORTALITY IN MEN WITH HIGH-RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
472	PD43-02 ARE WE OPERATING ON WHO WE SHOULD? THE CHANGING CHARACTERISTICS OF RADICAL PROSTATECTOMY PATIENTS: RESULTS FROM THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. Journal of Urology, 2016, 195, .	0.4	0
473	PD02-01 THE IMPACT OF FRAILTY ON COMPLICATIONS IN PATIENTS UNDERGOING COMMON UROLOGIC PROCEDURES; A STUDY FROM THE AMERICAN COLLEGE OF SURGEONS NATIONAL SURGICAL QUALITY IMPROVEMENT DATABASE. Journal of Urology, 2016, 195, .	0.4	0
474	PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
475	S&T-12 RACE DOES NOT PREDICT THE DEVELOPMENT OF METASTASES IN MEN WITH NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
476	PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.4	0
477	Is Surgery Still Necessary for Prostate Cancer?. , 2016, , 235-243.		Ο
478	S&T-25 ANDROGEN DEPRIVATION THERAPY IN THE CONTEXT OF DOSE ESCALATING RADIATION: COMMUNITY PRACTICE PATTERNS AND OUTCOMES. Journal of Urology, 2016, 195, .	0.4	0
479	PD17-11 THE GLOBAL BURDEN OF GENITOURINARY CANCER: GEOGRAPHIC AND TEMPORAL TRENDS IN MORBIDITY AND MORTALITY. Journal of Urology, 2016, 195, .	0.4	Ο
480	MP50-13 VALIDATION OF A BONE SCAN POSITIVITY RISK TABLE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
481	Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. European Urology, 2016, 69, 374-375.	1.9	0
482	PD71-05 VALIDATION OF GEMCAP AS A DNA BASED BIOMARKER TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
483	PD10-11 ANALYSIS OF THE PREDICTIVE UTILITY OF PROGNOSTIC GRADE GROUPS (PGG) FOR PREDICTING PERIOPERATIVE ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. Journal of Urology, 2017, 197, .	0.4	0
484	PD40-12 DO SICKER PEOPLE HAVE WORSE PROSTATE CANCER-SPECIFIC OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULTS FROM SEARCH. Journal of Urology, 2017, 197, .	0.4	0
485	MP64-09 THE IMPACT OF LYMPH NODES COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN MEN WITH LYMPH NODE METASTASIS AT THE TIME OF RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
486	PNFBA-09 THE DIVERSE GENOMIC LANDSCAPE OF LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0

#	Article	IF	CITATIONS
487	PD15-05 REAL-WORLD OUTCOMES OF OPEN VERSUS ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
488	MP14-02 THE NATURAL HISTORY OF MEN ON ACTIVE SURVEILLANCE WITH LOW-RISK PROSTATE CANCER ATÂA SAFETY-NET, COUNTY HOSPITAL. Journal of Urology, 2017, 197, .	0.4	0
489	MP20-02 NOVEL RISK STRATIFICATION GROUPING USING STANDARD CLINICAL AND BIOPSY INFORMATION FOR PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM SEARCH. Journal of Urology, 2017, 197, .	0.4	0
490	MP20-19 WHAT ARE THE BEST CUT-POINTS FOR PSA DOUBLING TIME IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER?. Journal of Urology, 2017, 197, .	0.4	0
491	PD47-10 THE RESEARCH IMPLICATIONS OF PSA REGISTRY ERRORS. Journal of Urology, 2017, 197, .	0.4	0
492	PD24-09 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER VISCERAL METASTASES PREDICTS SHORTER OVERALL SURVIVAL: WHAT PREDICTS VISCERAL METASTASES? RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2017, 197, .	0.4	0
493	PD28-04 THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION-BASED COHORT. Journal of Urology, 2017, 197, .	0.4	0
494	PD28-12 EFFECTS OF INITIAL GLEASON GRADE ON OUTCOMES DURING ACTIVE SURVEILLANCE FOR PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
495	MP43-11 REFINED ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA) VELOCITY TO PREDICT OUTCOMES IN ACTIVE SURVEILLANCE: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS). Journal of Urology, 2017, 197, .	0.4	0
496	MP47-09 TIMING OF PSA NADIR AFTER RADICAL PROSTATECTOMY AND RISK OF BIOCHEMICAL RECURRENCE: DOES IT MATTER? RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2017, 197, .	0.4	0
497	PD03-08 IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
498	PD03-10 VALIDATION OF THE 2015 PROSTATE CANCER PROGNOSTIC GRADE GROUPS FOR PREDICTING LONG-TERM ONCOLOGIC OUTCOMES IN A SHARED EQUAL ACCESS HEALTH SYSTEM Journal of Urology, 2017, 197, .	0.4	0
499	MP96-10 INITIAL VALIDATION OF AUTOMATED DATA EXTRACTION METHODS IN UROLOGIC ONCOLOGY PRACTICE. Journal of Urology, 2017, 197, .	0.4	0
500	MP20-09 EVALUATING MRI FUSION BIOPSY VS SYSTEMATIC ULTRASOUND GUIDED BIOPSY IN PREDICTING HIGH GRADE CANCER AT TIME OF RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
501	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. Journal of Urology, 2017, 198, 743-744.	0.4	0
502	How Should a Man with Prostate Cancer Choose his Surgeon?. European Urology, 2018, 73, 826-827.	1.9	0
503	Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. European Urology, 2018, 73, 477-478.	1.9	0
504	The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa044.	2.9	0

#	Article	IF	CITATIONS
505	Evaluation of the 4K score and MRI for the detection of high-grade prostate cancer. European Urology Open Science, 2020, 19, e172-e173.	0.4	Ο
506	683P Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database. Annals of Oncology, 2020, 31, S543.	1.2	0
507	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer, 2020, 126, 2935-2937.	4.1	Ο
508	Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304–6. European Urology, 2021, 79, e16.	1.9	0
509	Single-cell analysis of cellular state heterogeneity in human localized prostate cancer Journal of Clinical Oncology, 2021, 39, 254-254.	1.6	Ο
510	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press. European Urology Oncology, 2021, 5, 261-261.	5.4	0
511	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urologic Oncology: Seminars and Original Investigations. 2021. 40. 56.e1-56.e1.	1.6	0
512	B2B: Prostate Cancer. Société Internationale D'urologie Journal, 2021, 2, S30-S50.	0.4	0
513	The Art and Science of Risk Stratification in Localized Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2007, 3, 101-105.	0.1	0
514	Robot-Assisted Radical Prostatectomy: A Prostate Surgeon's Perspective. , 2011, , 255-260.		0
515	External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian Journal of Andrology, 2012, 14, 132-133.	1.6	0
516	Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort Journal of Clinical Oncology, 2012, 30, 10-10.	1.6	0
517	Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer. , 2013, , 593-605.		Ο
518	RE: Proximal bulbar periurethral abscess. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 186-187.	1.5	0
519	Patient-specific meta-analysis (MA) of two validation studies to predict pathologic outcomes in prostate cancer (PCa) using a 17-gene genomic prostate score (GPS) Journal of Clinical Oncology, 2016, 34, 100-100.	1.6	0
520	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry Journal of Clinical Oncology, 2016, 34, 320-320.	1.6	0
521	Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance Journal of Clinical Oncology, 2016, 34, 124-124.	1.6	0
522	Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy Journal of Clinical Oncology, 2016, 34, 76-76.	1.6	0

#	Article	IF	CITATIONS
523	Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined?. , 2016, , 33-52.		0
524	External validation of a prognostic Gleason grade classification system Journal of Clinical Oncology, 2016, 34, 123-123.	1.6	0
525	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry Journal of Clinical Oncology, 2016, 34, e16503-e16503.	1.6	0
526	Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index Journal of Clinical Oncology, 2016, 34, e16572-e16572.	1.6	0
527	Luminal and basal subtyping of prostate cancer Journal of Clinical Oncology, 2017, 2017, 3-3.	1.6	0
528	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy Journal of Clinical Oncology, 2017, 35, 110-110.	1.6	0
529	Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer Journal of Clinical Oncology, 2017, 35, 58-58.	1.6	0
530	Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer Journal of Clinical Oncology, 2017, 35, 5057-5057.	1.6	0
531	Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression Journal of Clinical Oncology, 2017, 35, e16566-e16566.	1.6	0
532	A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT) Journal of Clinical Oncology, 2017, 35, TPS5097-TPS5097.	1.6	0
533	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy Journal of Clinical Oncology, 2017, 35, e23055-e23055.	1.6	0
534	Active Surveillance in African-Americans. , 2018, , 53-58.		0
535	When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer Journal of Clinical Oncology, 2018, 36, 140-140.	1.6	0
536	Prostate 8 study: A pilot randomized controlled trial (RCT) of a web-based lifestyle intervention versus control group among men with prostate cancer Journal of Clinical Oncology, 2018, 36, 105-105.	1.6	0
537	The diverse genomic landscape of lowâ~'risk prostate cancer Journal of Clinical Oncology, 2018, 36, 74-74.	1.6	0
538	Development and pilot testing of a decision support intervention for men with prostate cancer Journal of Clinical Oncology, 2018, 36, 132-132.	1.6	0
539	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry Journal of Clinical Oncology, 2018, 36, 5041-5041.	1.6	0
540	Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance Journal of Clinical Oncology, 2019, 37, 88-88.	1.6	0

#	Article	IF	CITATIONS
541	A 17-gene genomic prostate score as a predictor of adverse pathology for men on active surveillance Journal of Clinical Oncology, 2019, 37, 97-97.	1.6	0
542	Radium-223 treatment patterns in a large real-world population Journal of Clinical Oncology, 2019, 37, 190-190.	1.6	0
543	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer Journal of Clinical Oncology, 2020, 38, 300-300.	1.6	0
544	Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis. , 2020, , .		0
545	Abstract D124: Racial differences in adverse pathology among men with prostate cancer at time of radical prostatectomy. , 2020, , .		0
546	Reply by Authors. Journal of Urology, 2020, 204, 1221-1221.	0.4	0
547	Reply by Authors. Journal of Urology, 2020, 203, 127-127.	0.4	0
548	Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer Journal of Clinical Oncology, 2020, 38, 290-290.	1.6	0
549	Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	0
550	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.5	0